Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
MNMD 
Mind Medicine Inc (MNMD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: MNMD (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
11 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $25
1 Year Target Price $25
| 7 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 48.02% | Avg. Invested days 32 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 749.47M USD | Price to earnings Ratio - | 1Y Target Price 25 |
Price to earnings Ratio - | 1Y Target Price 25 | ||
Volume (30-day avg) 11 | Beta 2.94 | 52 Weeks Range 4.70 - 11.02 | Updated Date 08/28/2025 |
52 Weeks Range 4.70 - 11.02 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.33 |
Earnings Date
Report Date 2025-07-31 | When - | Estimate -0.37 | Actual -0.5 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -30.55% | Return on Equity (TTM) -59.11% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 607664238 | Price to Sales(TTM) - |
Enterprise Value 607664238 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -6.57 | Shares Outstanding 76087904 | Shares Floating 70245911 |
Shares Outstanding 76087904 | Shares Floating 70245911 | ||
Percent Insiders 0.84 | Percent Institutions 55.68 |
Upturn AI SWOT
Mind Medicine Inc
Company Overview
History and Background
Mind Medicine Inc. (MindMed) was founded in 2019. It focuses on discovering, developing, and deploying psychedelic-inspired medicines and therapies to address addiction and mental health. They have been exploring various clinical trials for psychiatric disorders.
Core Business Areas
- Drug Development: Focuses on developing psychedelic-inspired drug candidates for mental health conditions. This includes clinical trials and research into LSD, psilocybin, and other substances.
- Digital Therapeutics: Development of digital tools and technologies to support mental health treatment and enhance the effectiveness of psychedelic-assisted therapies.
Leadership and Structure
The leadership team includes executives with experience in pharmaceuticals and drug development. The organizational structure typically involves research, clinical development, and commercialization teams.
Top Products and Market Share
Key Offerings
- MM-120 (LSD D-tartrate): A drug candidate being developed for generalized anxiety disorder (GAD). Clinical trials are ongoing. There is currently no market share, as it is not yet approved. Competitors include traditional anxiety medications and other emerging psychedelic therapies.
- R( - )-MDMA: A drug candidate being developed for autism spectrum disorder. Clinical trials are ongoing. There is currently no market share, as it is not yet approved. Competitors include current autism therapies and other emerging psychedelic therapies.
Market Dynamics
Industry Overview
The psychedelic medicine industry is emerging, with increasing interest in alternative treatments for mental health. Regulatory hurdles and public perception remain significant challenges.
Positioning
MindMed is positioned as a key player in the psychedelic medicine space, focusing on rigorous clinical trials and scientific validation. Their competitive advantage lies in their diverse pipeline and experienced team.
Total Addressable Market (TAM)
The TAM for mental health treatments is substantial, estimated to be in the tens of billions of dollars. MindMed's success hinges on securing regulatory approvals and market adoption of their therapies.
Upturn SWOT Analysis
Strengths
- Strong intellectual property portfolio
- Experienced management team
- Focus on scientific validation
- Diverse pipeline of drug candidates
Weaknesses
- High cash burn rate
- Regulatory uncertainty
- Limited revenue generation
- Public perception challenges
Opportunities
- Regulatory approvals for psychedelic therapies
- Partnerships with pharmaceutical companies
- Expansion into new indications
- Growing acceptance of psychedelic medicine
Threats
- Clinical trial failures
- Increased competition
- Changes in regulatory landscape
- Negative publicity
Competitors and Market Share
Key Competitors
- atai Life Sciences N.V. (ATAI)
- COMPASS Pathways plc (CMPS)
Competitive Landscape
MindMed faces competition from other companies developing psychedelic therapies. The competitive landscape is characterized by innovation and scientific rigor. Currently no revenues can allow to determine marketshare. All companies involved are still in the drug discovery phase.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been characterized by increasing R&D spending and clinical trial progress.
Future Projections: Future growth is contingent on successful clinical trials, regulatory approvals, and market adoption. Analyst projections vary widely.
Recent Initiatives: Recent initiatives include advancing clinical trials for MM-120 and R(-)-MDMA and seeking regulatory guidance.
Summary
MindMed is a clinical-stage company developing psychedelic therapies. Success depends on clinical trial outcomes and regulatory approvals. The company has a strong intellectual property portfolio but also faces significant financial and regulatory challenges. The emerging psychedelic medicine industry presents both opportunities and risks.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Press releases
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. The data provided is based on available information and may be subject to change. Investing in speculative companies like MindMed involves significant risks.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Mind Medicine Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2020-03-03 | CEO & Director Mr. Robert Barrow | ||
Sector Healthcare | Industry Biotechnology | Full time employees 74 | Website https://www.mindmed.co |
Full time employees 74 | Website https://www.mindmed.co | ||
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.